Gene

EPHA2

EPH receptor A2

Curated evidence

Clinical evidence (2)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EPHA2 Expression2
Dasatinib + TrametinibCombination	Uterine Corpus Endometrial CarcinomaUNRESOLVED	Predictive	C	Supports Sensitivity Response	2	submitted	EID12577 In uterine corpus endometrial carcinoma (TCGA, n = 382), EPHA2 overexpression correlated with JAG1, MYC, NOTCH1, NOTCH3, and HES1 expression (Spearman r = 0.25-0.43; p < 0.01). Elevated MAP3K15, DLL3,… (full text at CIViC) PMID 34391578 · Wu et al., 2021 · Open in CIViC	civic
〃	Malignant Uterine NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID12576 In a preclinical study of uterine cancer cell lines resistant to EphA2 inhibitors (HEC-1A, Ishikawa, RL-95), EphA2-positive cells treated with the MEK inhibitor trametinib restored sensitivity to dasa…

Cohorts

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved23 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Kidney Chromophobe TCGA-KICH	Chromophobe Renal Cell Carcinoma	Ssm

Literature

Data not yet available

No publication linked to this gene yet.